• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Schultz Edward Christopher

    4/1/26 6:42:32 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CAPS alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    SCHULTZ EDWARD CHRISTOPHER

    (Last)(First)(Middle)
    5141 W. 122ND STREET

    (Street)
    ALSIP ILLINOIS 60803

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Capstone Holding Corp. [ CAPS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director10% Owner
    XOfficer (give title below)Other (specify below)
    Chief Financial Officer
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    03/30/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Restricted Stock Award(1)$003/30/2026A190,000 (1) (1)Common Stock190,000$0.649190,000D
    Explanation of Responses:
    1. The RSUs vest in full on March 30, 2029, which is the third anniversary of the March 30, 2026 grant date, subject to the Reporting Person's continued service through such vesting date.
    /s/ Edward Schultz04/01/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $CAPS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAPS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CAPS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Schultz Edward Christopher

    4 - Capstone Holding Corp. (0000887151) (Issuer)

    4/1/26 6:42:32 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Lipman Matthew E.

    4 - Capstone Holding Corp. (0000887151) (Issuer)

    4/1/26 6:41:21 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Toporek Michael

    4 - Capstone Holding Corp. (0000887151) (Issuer)

    4/1/26 6:40:16 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CAPS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Capstone Announces Investor FAQ Focused on 2026 Guidance and Earnings

    Company invites shareholder submissions; FAQ to expand on growth trajectory, margin profile, and path to profitability Capstone Holding Corp. (NASDAQ:CAPS), a tech-enabled building products distribution platform, will publish an investor FAQ during the week of May 4, addressing key questions from its shareholder base. The FAQ will provide additional detail on the Company's recent earnings and 2026 guidance, which includes 54% revenue growth and approximately 4x EBITDA growth. Ahead of publication, Capstone is inviting shareholders to submit questions by emailing [email protected]. Submissions will be reviewed by the Company's leadership team, with a selection of response

    4/21/26 7:30:00 AM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capstone Reports FY2025 Results and Guides to 54% Revenue Growth and 4x EBITDA Growth in 2026

    FY2025 gross margin expands to 23% on $46.9M revenue; FY2026 guidance calls for $72.1M of revenue, ~$18.7M of gross profit (+73%), and a positive EBITDA run-rate starting in Q2 Capstone Holding Corp. (NASDAQ:CAPS), a tech-enabled building products distribution platform, today announced financial and operating results for the fourth quarter and full year ended December 31, 2025. The Company closed FY2025 with ~$46.9 million in revenue and gross margin expanding to 23.0%, reflecting acquisition-driven scale and a higher-margin product mix. For FY2026, Capstone expects revenue to rise 54% to $72.1 million, gross margin to reach 26%, and EBITDA to increase more than fourfold to approximatel

    4/16/26 7:30:00 AM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capstone Awarded Eldorado Stone Distribution, Targeting $5 Million in Organic Revenue Growth

    $5 million in organic revenue sold through existing distribution channels with no incremental investment; share-of-wallet capture from existing customers accelerates near-term revenue ramp Capstone Holding Corp. (NASDAQ:CAPS), a tech-enabled building products distribution platform, today announced it has been awarded distribution rights for Eldorado Stone, a premium manufactured stone veneer brand from Westlake Royal Building Products. The Company expects the addition will contribute $5 million in annualized run-rate revenue by Q3 2027, sold entirely through Capstone's existing distribution channels with no incremental infrastructure investment. Capstone is already a top-three national

    4/6/26 7:30:00 AM ET
    $CAPS
    $WLK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Chemicals
    Industrials

    $CAPS
    SEC Filings

    View All

    Amendment: SEC Form 10-K/A filed by Capstone Holding Corp.

    10-K/A - Capstone Holding Corp. (0000887151) (Filer)

    4/17/26 5:15:36 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 10-K/A filed by Capstone Holding Corp.

    10-K/A - Capstone Holding Corp. (0000887151) (Filer)

    4/17/26 4:10:39 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capstone Holding Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Capstone Holding Corp. (0000887151) (Filer)

    4/16/26 3:09:28 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care